DB16384InvestigationalProtein Based Therapies
Toralizumab is under investigation in clinical trial NCT03605927 (CD40-L Blockade for Prevention of Acute Graft-versus-host Disease).
- Mechanism
- Curator reviewed
Pharmacologically active on CD40 ligand
- Also known as
- Anti-CD 154 human-mouse monoclonal antibody · Anti-CD40L · Anti-GP39
- Code names
- ANTI-CD154 · E-6040 · IDEC-131
Resolves to
Compound
Targets
What you can answer from here — as of June 15, 2026
Which drugs share a target with Toralizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account